Infigo Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 14.62 Cr
as on 15-11-2024
- Paid Up Capital ₹ 7.83 M
as on 15-11-2024
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 20.48%
(FY 2023)
- Profit -241.61%
(FY 2023)
- Ebitda -115.09%
(FY 2023)
- Net Worth 102.01%
(FY 2023)
- Total Assets 32.14%
(FY 2023)
About Infigo Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 14.62 Cr and a paid-up capital of Rs 7.83 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Infigo Lifesciences Private Limited India is Shridhar Raghunath as CEO. Anil Kamath and Shridhar Raghunath serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC300119
- Company No.
300119
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Sep 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Infigo Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shridhar Raghunath  | Managing Director | 26-Sep-2017 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anil Kamath | Director | 26-Sep-2017 | Current |
Financial Performance and Corporate Structure Insights of Infigo Lifesciences.
Infigo Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.48% increase. The company also saw a substantial fall in profitability, with a 241.61% decrease in profit. The company's net worth Soared by an impressive increase of 102.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Infigo Lifesciences?
In 2023, Infigo Lifesciences had a promoter holding of 89.33% and a public holding of 10.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Infigo Lifesciences?
Infigo Lifesciences has a workforce of 98 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Infigo Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infigo Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
